Eyetech Pharmaceuticals is a biopharmaceutical company that specializes in novel therapeutics to treat diseases of the eye.
Business Model:
Revenue: $0
Employees: 201-500
Eyetech Pharmaceuticals was acquired by
Bausch Health.
The acquisition happend on 2012-02-13.
Details of the transaction were not public
Address:
City: New York
State: New York
Zip:
Country: United States
Eyetech Pharmaceuticals is a biopharmaceutical company that specializes in novel therapeutics to treat diseases of the eye. The company conducted research and development into wet age-related macular degeneration diseases, which was seen as a breakthrough in the field. Valeant Pharmaceuticals International acquired Eyetech for US$22 million in 2012.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
1/30/2004
IPO Valuation:
$809M
Ticker Symbol:
EYET
IPO Price:
$21/share
Amount Raised:
$137M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2001 | Series C | 6 | $108.5M |
JPMorgan Partners BB Biotech Ventures Alta Partners Schroder Ventures Merrill Lynch MPM Capital JPMorgan Partners JPMorgan Partners BB Biotech Ventures Alta Partners Schroder Ventures Merrill Lynch MPM Capital JPMorgan Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|